Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFKXMT)

• Drug Name: BW-202W92 Drug Info
• Synonyms: BW-202W92; SCHEMBL136398; CHEMBL448556; QEDNOUAODRFJQN-UHFFFAOYSA-N; BW202W92; 2.4-Diamino-5-(2,3,5-trichlorophenyl)-6-fluoromethylpyrimidine; 2,4-diamino-5-(2,3,5-trichlorophenyl)-6-fluoromethylpyrimidine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9883607
  TTD Drug ID: DMFKXMT

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.4 (SCN4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanperisone	DM4EGPN	Musculoskeletal disorder	FA00-FC0Z	Phase 3	[2]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[1]
V-102862	DMR2EUV	N. A.	N. A.	Discontinued in Phase 1	[3]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[4]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[4]
CCNCSSKWCRDHSRCC	DMBGHTW	Discovery agent	N.A.	Investigative	[5]
CCNCSSKWCRAHSRCC	DM96YR2	Discovery agent	N.A.	Investigative	[5]
CCACSSKWCRDHSRCC	DMSE20Y	Discovery agent	N.A.	Investigative	[5]
CCNCASKWCRDHSRCC	DMRFA5O	Discovery agent	N.A.	Investigative	[5]
ZNCCNCSSKWCRDHSRCC	DMY2V37	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[6]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[7]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[8]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[9]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[10]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[11]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[12]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[13]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[14]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[15]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[16]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[17]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[17]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[18]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[19]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[17]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[20]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[13]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[21]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[22]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[10]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[23]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[23]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[23]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[23]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[23]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[24]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[25]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[10]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.4 (SCN4A)	TT84DRB	SCN4A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[1]

References

• [1] Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
• [2] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [3] 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
• [4] Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
• [5] Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
• [6] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [7] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [8] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [9] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [10] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [11] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [12] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [15] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [16] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [18] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [19] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [20] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [21] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [22] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.
• [23] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [24] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [25] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).